Month: March 2025

LiveWorld looks to increase its AI investment CAMPBELL, Calif. and NEW YORK , March 25, 2025 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2024. Twelve Months 2024 Financial and Business HighlightsTotal twelve months revenues of $11.3 million, a 1% reduction from 2023 Healthcare revenues of $10.2 million in 2024 Net income from operations of $69,000 Net Cash increased by $1.6 million to $6.2 million from December 31, 2023Management Commentary “In 2024 our top line revenues were relatively flat compared to 2023 as clients constrained their marketing budgets year-to-year,“ remarked David Houston, Chief Financial Officer of LiveWorld. “We were able to end the year with a positive net income of $69,000 even as we made investments for future growth. While we anticipate continued...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “We made excellent progress across our pipeline...

Quadruple Digit % Gains Year-Over-Year and Triple Digit % Gains Quarter-Over-Quarter Reflected in 2024 Form 10-K Debt-Free and $13.50 Cash Value Per Common Share* Increased Growth Projected For Q1 2025 LAS VEGAS and LOS ALAMITOS, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), Transforming the Landscape of Social Commerce, Social Telehealth and Social Crowdfunding with MARKET.live; VANITYPrescribed; GoodGirlRx; and the GO FUND YOURSELF TV Show, today filed its Form 10-K reporting financial and operating results for the full year and the quarter ending December 31, 2024. Summary Financial Results For the Year Ended December 31, 2024Total revenue was $895 thousand, an increase of $832 thousand, or 1,321%, over the previous year. Represents...

~ Record Revenues of $30.2 Million, Up 48% Year-over-Year ~ ~ MAUs of 68 Million, Including 21% Sequential Growth in the U.S. and Canada to 52 Million ~ ~ Received $775 Million Strategic Investment from Tether ~ ~ Fifth Consecutive Quarter of Reduced Cash Usage, 19% Less Than Prior Quarter ~ LONGBOAT KEY, Fla., March 25, 2025 (GLOBE NEWSWIRE) — Rumble Inc. (Nasdaq: RUM) (“Rumble” or the “Company”), the video-sharing platform and cloud services provider, today announced financial results for the fiscal fourth quarter and full year ended December 31, 2024. Q4 2024 Key Highlights and Key ItemsRevenue for the fourth quarter was $30.2 million, an increase of 48% compared to $20.4 million in the fourth quarter of 2023. Average global Monthly Active Users (“MAUs”) of 68 million in the fourth quarter of 2024, compared to 67 million...

SECAUCUS, N.J., March 25, 2025 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty retailer in North America with an omni-channel portfolio of brands and an industry-leading digital-first model, today announced that their fourth quarter and year-end fiscal 2024 financial results, and Turki S. AlRajhi’s annual letter to shareholders, will be released on Friday, April 11, 2025 at approximately 4:30 p.m. Eastern Time where it can be accessed at https://corporate.childrensplace.com/. About The Children’s Place The Children’s Place is the largest pure-play children’s specialty retailer in North America with an omni-channel portfolio of brands and an industry-leading digital-first model. Its global retail and wholesale network includes two digital storefronts, more than 500 stores...

Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 HighlightsStrategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic breast cancer. The Company believes this approach may offer a more streamlined regulatory pathway to deliver (Z)-endoxifen to patients with urgent...

‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights:CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in July 2024 and first partial year of DefenCath sales. The Company reported net sales of $31.2 million for the fourth quarter and $43.5 million for full year...